GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GSK plc GSK.L · GBp

Health Care · Pharmaceuticals · LSE · 🇬🇧 United Kingdom

FTSE 100

Compare

1,904.50p

+0.77%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in GBP, from our data supplier.

FY2025

Revenue

£32.67bn

FY2016FY2025

Net income

£5.72bn

FY2016FY2025

Free cash flow

£5.96bn

FY2016FY2025

Shareholders' equity

£16.38bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue£32.67bn£31.38bn£30.33bn£29.32bn£24.70bn£34.10bn£33.75bn£30.82bn£30.19bn£27.89bn
Gross profit£23.70bn£21.90bn£21.25bn£19.46bn£16.34bn£23.12bn£22.89bn£20.93bn£20.09bn£18.44bn
Research and development£7.51bn£5.50bn£5.25bn£4.84bn£4.39bn£4.48bn£4.25bn£3.66bn£3.87bn£3.48bn
Operating income£7.80bn£5.66bn£6.99bn£6.68bn£5.41bn£8.18bn£7.78bn£8.00bn£7.97bn£6.83bn
Net income£5.72bn£2.58bn£4.93bn£14.96bn£4.38bn£5.75bn£4.64bn£3.62bn£1.53bn£912.0m
Diluted earnings per share1.400.621.203.661.351.431.160.910.390.23

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets£61.12bn£59.46bn£59.01bn£60.15bn£79.10bn£80.43bn£79.69bn£58.07bn£56.38bn£59.08bn
Cash and short-term investments£3.16bn£3.71bn£4.99bn£7.68bn£4.13bn£6.17bn£4.59bn£3.96bn£3.91bn£4.99bn
Total liabilities£45.16bn£46.38bn£46.21bn£50.05bn£57.76bn£59.62bn£61.34bn£54.39bn£52.89bn£54.12bn
Debt£17.72bn£16.99bn£18.02bn£20.99bn£24.17bn£27.15bn£30.51bn£26.06bn£17.09bn£18.79bn
Shareholders' equity£16.38bn£13.67bn£13.35bn£10.60bn£15.05bn£14.59bn£11.40bn£3.78bn−£68.0m£1.12bn
Shares outstanding4,086m4,145m4,118m4,091m3,246m4,034m4,018m3,982m3,913m3,932m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations£7.30bn£6.55bn£6.77bn£7.40bn£7.95bn£8.44bn£8.02bn£8.42bn£6.92bn£6.50bn
Capital spending−£1.35bn−£2.98bn−£2.34bn−£2.26bn−£2.93bn−£2.24bn−£2.16bn−£1.80bn−£2.20bn−£2.35bn
Free cash flow£5.96bn£3.57bn£4.42bn£5.14bn£5.02bn£6.20bn£5.86bn£6.63bn£4.72bn£4.14bn
Dividends paid−£2.56bn−£2.44bn−£2.25bn−£3.47bn−£4.00bn−£3.98bn−£3.95bn−£3.93bn−£3.91bn−£4.85bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue£8.41bn£7.63bn£8.62bn£8.55bn£7.99bn£7.52bn£8.12bn£8.01bn
Gross profit£6.31bn£5.75bn£5.98bn£6.29bn£5.82bn£5.59bn£5.58bn£5.68bn
Operating income£2.40bn£2.29bn£973.0m£2.59bn£1.85bn£2.14bn£736.0m£221.0m
Net income£435.0m£1.74bn£636.0m£2.01bn£1.44bn£1.62bn£414.0m−£58.0m
Diluted earnings per share0.110.430.160.490.350.400.10-0.01
Cash from operations£2.53bn£1.14bn£2.09bn£2.22bn£2.10bn£1.15bn£2.33bn£2.15bn
Capital spending−£328.0m−£443.0m−£573.0m−£879.0m−£633.0m−£448.0m−£1.14bn−£305.0m
Free cash flow£2.20bn£698.0m£1.52bn£1.34bn£1.46bn£697.0m£1.19bn£1.85bn
Total assets£61.74bn£62.87bn£61.12bn£61.34bn£59.26bn£60.70bn£59.46bn£58.05bn
Cash and short-term investments£3.11bn£3.44bn£3.16bn£3.31bn£3.62bn£4.49bn£3.71bn£3.21bn
Debt£4.29bn£5.04bn£17.03bn£2.86bn£2.05bn£1.96bn£16.05bn£2.81bn
Shareholders' equity£17.64bn£17.85bn£16.38bn£16.15bn£14.79bn£14.16bn£13.67bn£14.01bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.7%-0.9%3.2%
Operating income5.3%-0.9%5.7%
Net income-27.4%-0.1%-3.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin71.2%69.8%68.9%67.8%
Operating margin21.0%21.9%22.3%23.0%
Net margin12.9%22.8%21.0%17.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings13.021.712.13.912.09.515.516.534.067.8
Price to sales2.31.82.02.02.11.62.11.91.72.2

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 13 Aug 2026.

FY2026FY2024FY2023FY2022FY2021FY2020FY2018FY2017
Paid in the year0.340.820.810.420.6132.001.2872.00
  • 5-to-4 reverse split · 19 Jul 2022
  • 1-to-1 reverse split · 27 Dec 2000
  • 2-for-1 split · 28 Oct 1991
  • 2-for-1 split · 24 Nov 1989

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.